Daiwa Securities Group Inc. Has $4.80 Million Stock Position in Celgene Co. (NASDAQ:CELG)

Daiwa Securities Group Inc. lifted its stake in shares of Celgene Co. (NASDAQ:CELG) by 0.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 48,322 shares of the biopharmaceutical company’s stock after purchasing an additional 145 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Celgene were worth $4,799,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CELG. Renaissance Technologies LLC grew its holdings in shares of Celgene by 85.7% during the 2nd quarter. Renaissance Technologies LLC now owns 8,935,785 shares of the biopharmaceutical company’s stock worth $826,024,000 after purchasing an additional 4,122,685 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in Celgene by 707.3% in the second quarter. Nuveen Asset Management LLC now owns 4,476,814 shares of the biopharmaceutical company’s stock valued at $413,836,000 after buying an additional 3,922,247 shares in the last quarter. York Capital Management Global Advisors LLC boosted its stake in Celgene by 854.8% in the second quarter. York Capital Management Global Advisors LLC now owns 2,588,825 shares of the biopharmaceutical company’s stock valued at $239,311,000 after buying an additional 2,317,676 shares in the last quarter. TIG Advisors LLC boosted its stake in Celgene by 77.3% in the second quarter. TIG Advisors LLC now owns 3,583,622 shares of the biopharmaceutical company’s stock valued at $331,270,000 after buying an additional 1,562,004 shares in the last quarter. Finally, Omni Partners LLP boosted its stake in Celgene by 207.0% in the second quarter. Omni Partners LLP now owns 1,842,219 shares of the biopharmaceutical company’s stock valued at $170,295,000 after buying an additional 1,242,219 shares in the last quarter. 72.31% of the stock is currently owned by institutional investors.

Celgene stock opened at $109.54 on Friday. The company has a current ratio of 2.89, a quick ratio of 2.80 and a debt-to-equity ratio of 1.51. The company has a market capitalization of $76.64 billion, a PE ratio of 14.39, a P/E/G ratio of 0.51 and a beta of 1.41. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $109.75. The stock has a 50-day moving average price of $102.54 and a two-hundred day moving average price of $96.76.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 EPS for the quarter, beating the consensus estimate of $2.70 by $0.29. The firm had revenue of $4.52 billion during the quarter, compared to the consensus estimate of $4.39 billion. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The business’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period last year, the company earned $2.29 earnings per share. As a group, analysts predict that Celgene Co. will post 10.7 earnings per share for the current fiscal year.

CELG has been the topic of several research analyst reports. BidaskClub raised Celgene from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective on the stock in a research note on Tuesday, July 23rd. Mizuho reaffirmed a “hold” rating and issued a $100.00 price objective on shares of Celgene in a research note on Sunday, October 20th. Standpoint Research lowered Celgene from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, ValuEngine lowered Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, nineteen have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $97.31.

In other Celgene news, insider Terrie Curran sold 11,338 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the transaction, the insider now directly owns 13,493 shares in the company, valued at $1,325,957.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.39% of the stock is currently owned by company insiders.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: Current Ratio

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.